ProCE Banner Activity

GFM COMBOLA Part A: Phase I/II Study of Luspatercept + EPO in Patients With Lower-Risk, Ring Sideroblast–Negative MDS After ESA Failure

Conference Coverage
Slideset

In Part A of the phase I/II GFM COMBOLA trial in patients with lower-risk, ring sideroblast–negative myelodysplastic syndromes after ESA failure, the combination of luspatercept and EPO had a manageable safety profile and resulted in an erythroid response in 30% of participants at Week 25.

Released: December 10, 2024

Expiration: December 09, 2025

Share

Provided by

Provided by Clinical Care Options, LLC 

ProCE Banner

Supporters

This educational activity is supported by independent medical educational grants from AstraZeneca, Bristol Myers Squibb, GlaxoSmithKline, Incyte Corporation, Lilly, and Novartis Pharmaceuticals Corporation.

AstraZeneca

Bristol Myers Squibb

GlaxoSmithKline

Incyte Corporation

Lilly

Novartis Pharmaceuticals Corporation